885518-49-0

Basic information

• Product Name: 6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER
• Synonyms: 6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER;Methyl 6-bromo-(1H)-indaz...;1H-Indazole-4-carboxylic acid, 6-broMo-, Methyl ester;6-BroMo-1H-indazole-4-carboxylic acid Methyl ester;6-BroMo-1H-indazol-4-carboxylic acid Methyl ester
• CAS NO: 885518-49-0
• Molecular Formula: C₉H₇BrN₂O₂
• Molecular Weight: 255.07
• Product Categories: Indazoles
• Mol File: 885518-49-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 395.877 °C at 760 mmHg
• Flash Point: 193.22 °C
• Appearance: /
• Density: 1.71 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.21±0.40(Predicted)
• CAS DataBase Reference: 6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER(885518-49-0)
• EPA Substance Registry System: 6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER(885518-49-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 885518-49-0(Hazardous Substances Data)

Usage

General Description

6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER is a chemical compound with the molecular formula C9H7BrN2O2. It is an indazole derivative that is used in the synthesis of pharmaceuticals and agrochemicals. 6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER is commonly utilized as a building block in the preparation of various biologically active molecules. It is also used as a reagent in organic synthesis to introduce the indazole group into various organic molecules. Additionally, 6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER has potential applications in the development of new drugs and in medicinal chemistry research.

Upstream product

• 67-56-1 methanol 
• 885523-08-0 6-bromo-1H-indazole-4-carboxylic acid 
• 59382-59-1 2-methyl-3-nitro-benzoic acid methyl ester 
• 118-90-1 ortho-methylbenzoic acid 
• 79669-49-1 5-bromo-2-methylbenzoic acid 
• 1346597-55-4 methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate 
• 1000342-11-9 2-methyl-3-amino-5-bromobenzoic acid methyl ester 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 220514-28-3 5-bromo-2-methyl-3-nitrobenzoic acid methyl ester 
• 107650-20-4 5-bromo-2-methyl-3-nitro-benzoic acid 

Downstream Products

• 1245465-61-5 methyl 6-bromo-1-[(4-methylphenyl)sulfonyl]-1H-indazole-4-carboxylate 
• 1346702-52-0 methyl 6-bromo-1-(1-methylethyl)-1H-indazole-4-carboxylate 
• 1396772-45-4 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-(morpholinomethyl)phenyl)-1H-indazole-4-carboxamide 
• 1396772-66-9 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-(3-(methylamino)propoxy)phenyl)-1H-indazole-4-carboxamide 
• 1396772-71-6 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-(3-(dimethylamino)propoxy)phenyl)-1H-indazole-4-carboxamide 
• 1396772-75-0 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-(3-(methylamino)propoxy)phenyl)-1H-indazole-4-carboxamide 
• 1396780-39-4 methyl 1-cyclopentyl-6-(3-hydroxyphenyl)-1H-indazole-4-carboxylate 
• 1396780-41-8 methyl 1-cyclopentyl-6-(3-(3-hydroxypropoxy)phenyl)-1H-indazole-4-carboxylate 
• 1396780-46-3 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-(3-hydroxypropoxy)phenyl)-1H-indazole-4-carboxamide 
• 1396780-42-9 C₂₂H₂₄N₂O₄ 
• 1396780-48-5 6-(3-(3-bromopropoxy)phenyl)-1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide 
• 1396780-50-9 methyl 1-cyclopentyl-6-(4-hydroxyphenyl)-1H-indazole-4-carboxylate 
• 1396780-51-0 methyl 1-cyclopentyl-6-(4-(3-hydroxypropoxy)phenyl)-1H-indazole-4-carboxylate 
• 1396780-52-1 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-(3-hydroxypropoxy)phenyl)-1H-indazole-4-carboxamide 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Pyridone derivatives and its preparation and use

The invention belongs to the field of chemical medicines, and particularly relates to a pyridone derivative, a preparation method and an application thereof. The pyridone derivative is represented as the formula (I). The invention also provides the prepar

SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS

The present invention relates to substituted 6,5 -fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.